NGEN Nervgen Pharma (NGEN) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001751912
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
40
13F, latest reported quarter
Nervgen Pharma insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for NERVGEN PHARMA CORP. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.
Canadian issuer: its insiders report trades in Canada on SEDI, not on SEC Form 4, so their buys and sells do not appear here.
Insider
Filed
Shares
Value
Since filing
no insider purchases or sales on record
0 transactions on record
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
40 funds bought in last quarter
below 57% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
6.1% of the float short (float per yahoo 2026-10-26) · 11.3 days to cover · settled 2026-09-30
more than 62% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch NGEN
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
Who owns NGEN: institutional holders (13F)
13F holdings, latest reported quarter
4,000,000 sh
$8.2M
1,208,231 sh
$2.5M
1,050,000 sh
$2.2M
1,000,000 sh
$2.1M
678,000 sh
$1.4M
Congress trades in NGEN
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
NGEN planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
NGEN mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Nasdaq Composite Index Fund
$31.8K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
3 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
0 active
1
Phase 3
1 active
1
Multi-phase
0 active
What changed recently
A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal
2026-09-30 · Not Yet Recruiting → Recruiting
Phase 3
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 40 funds added last quarter. Each figure is a federal filing, dated the day it went public.
NGEN financials
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | |
|---|---|---|
| Net income | -$44.1M | -$24.3M |
SEC XBRL, fiscal years, as known on 2026-10-27
NGEN Stock Sonar score 2/7 axes
Find similar shapesCompare2 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
